← back to search

Lars Henrik Jensen

University of Southern Denmark · DK
Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics, and Cholangiocarcinoma and Gallbladder Cancer Studies.
h-index
33
citations
8,149
works
295
NIH funding
primary concept
Medicine
email

Recent publications

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
The Lancet 2025cited by 162position: middledoi
Fear of cancer recurrence in long-term colorectal cancer survivors: a nationwide cross-sectional study
Journal of Cancer Survivorship 2025cited by 8position: middledoi
Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Journal of Clinical Oncology 2024cited by 75position: middledoi
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
Journal of Clinical Oncology 2024cited by 61position: middledoi
Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer
Journal of Clinical Oncology 2024cited by 28position: middledoi
LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
Annals of Oncology 2023cited by 21position: middledoi
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
The Lancet Oncology 2022cited by 872position: middledoi
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
The Lancet Oncology 2021cited by 217position: middledoi
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
New England Journal of Medicine 2020cited by 2,898position: middledoi
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer
Journal of Hepatology 2020cited by 37position: middledoi
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials
BMC Cancer 2017cited by 25position: middledoi
High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study
The Lancet Oncology 2015cited by 547position: middledoi
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
BMC Cancer 2015cited by 228position: middledoi
Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
Annals of Oncology 2015cited by 112position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Thierry André · Inserm6 papers (2020–2024)Rocio García‐Carbonero · Research Institute Hospital 12 de Octubre5 papers (2020–2024)Takayuki Yoshino · Kindai University5 papers (2020–2024)Luis A. Díaz · Secretaria de Salud4 papers (2020–2023)Christelle de la Fouchardière · Aix-Marseille Université4 papers (2020–2024)Denis Smith · Albion Centre4 papers (2020–2023)John Bridgewater · University College Hospital4 papers (2015–2020)Benny Vittrup Jensen · Gentofte Hospital4 papers (2020–2023)Dung T. Le · Johns Hopkins University4 papers (2020–2023)David Goldstein · University Health Network4 papers (2015–2020)Mairéad G. McNamara · Australian and New Zealand Intensive Care Society3 papers (2015–2020)Cornelis J.A. Punt · Oklahoma State University Center for Health Sciences3 papers (2020–2022)Peter Gibbs · Dubbo Hospital3 papers (2020–2023)David Cunningham · Centre de recherche en Epidémiologie et Santé des Populations3 papers (2015–2020)Harpreet Wasan · Imperial College Healthcare NHS Trust3 papers (2015–2020)Jennifer J. Knox · Ontario Institute for Cancer Research3 papers (2015–2020)Dorothea Wagner · University of Lausanne3 papers (2015–2020)Tanios Bekaii‐Saab · WinnMed3 papers (2015–2020)Takuji Okusaka · National Cancer Center3 papers (2015–2020)Juan W. Valle · Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele3 papers (2015–2020)